Sir David Lane
Chairman of the Board
With its proprietary antibody engineering and cyclic peptide research technologies, CPR has great potential to create a world-leading technology platform that transforms the efficacy of antibody and cyclic-based drugs. At the same time, CPR can leverage on this technology to contribute to a community of innovation. Since its establishment, CPR has increasingly embedded itself into Singapore’s vibrant research scene through its research performance and involvement in external activities such as the organisation of antibody symposiums. As a result, expectations from others have also been increasing. I am very proud to help CPR generate a pipeline of innovative products that will help patients around the world. I am also pleased to help CPR foster closer interactions with Singapore’s international research community.